The Luxturna Debate: Why Ethics Needs a Seat at the Drug Pricing Table
Jack Hogan can now ride his bike home at dusk after an afternoon of playing with his friends. Is that childhood rite-of-passage worth $850,000?
Drug Pricing
-
Read more: The Luxturna Debate: Why Ethics Needs a Seat at the Drug Pricing Table -
Read more: Drug Pricing Controls and the Power of Familiar Ideas Drug Pricing Controls and the Power of Familiar Ideas
By Mark Satta Eight in ten Americans think that prescription drug prices are unreasonable, according to a March 2018 Kaiser poll. That same poll found that more Americans considered passing legislation to lower drug pricing to be a top priority than passing legislation to improve infrastructure or to address the prescription painkiller epidemic, among other…
-
Read more: Step therapy explained: An increasingly popular tool for cost control Step therapy explained: An increasingly popular tool for cost control
News that the Centers for Medicare and Medicaid Services will allow Medicare Advantage programs to enact “step therapy” programs for drugs under Part B as part of an effort to combat rising drug prices has been making rounds in the health policy world recently. Step therapy is used by all major private insurers and is…
-
Read more: World Trade Month: Trade’s impact on domestic drug prices World Trade Month: Trade’s impact on domestic drug prices
By Oliver Kim Happy World Trade Month! While health policy is often seen as something particularly domestic, trade can have an impact on health policy here at home. Just a day before President Trump’s speech outlining the administration’s approach to rising drug costs, the Pharmaceutical Research and Manufacturers of America (PhRMA) declared May as a…
-
Read more: CMS Issues Notice Regarding Barriers to HCV Treatment CMS Issues Notice Regarding Barriers to HCV Treatment
By Dalia Deak Yesterday, the Centers for Medicare & Medicaid Services (CMS) issued a notice that affirmed CMS’s commitment to provide prescription drugs to beneficiaries, specifically highlighting beneficiaries suffering from hepatitis C virus (HCV). The notice comes at a moment of heightened interest in the cost of prescription drugs (particularly on the federal level as…
-
Read more: A New Cholesterol-Lowering Drug at What Price? A New Cholesterol-Lowering Drug at What Price?
By Kate Greenwood [Cross-posted at Health Reform Watch] This summer, the Food and Drug Administration (FDA) is expected to approve the first entries in a new class of drugs that lower patients’ low-density lipoprotein (LDL) cholesterol levels by more than half, even those patients who are already taking other cholesterol-lowering medication. The new drugs are biologics—monoclonal…
-
Read more: The Tylenol Debate: Can Hospitals be Sued for Excessive Markups on Medications and Devices? The Tylenol Debate: Can Hospitals be Sued for Excessive Markups on Medications and Devices?
By Alex Stein Steven Brill’s TIME MAGAZINE blockbuster article, Bitter Pill: Why Medical Bills are Killing Us, uncovers the CHARGEMASTER: a publicly undisclosed pricelist accountable for what we see in hospital bills. What we see there doesn’t look good: it includes acetaminophen sold for $1.50 a tablet (you can buy 100 of those for the…